Clinical significance and gene expression study of human hepatic stellate cells in HBV related-hepatocellular carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Liao, Rui ^a,b   Wu, Han ^a,b   Yi, Yong ^a,b   Wang, Jia Xing ^a,b   Cai, Xiao Yan ^a,b   He, Hong Wei ^a,b   Cheng, Yun Feng ^a   Zhou, Jian ^a,b   Fan, Jia ^a,b   Sun, Jian ^a,b   Qiu, Shuang Jian ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Gene expression; Hepatic stellate cell; Hepatocellular carcinoma; Phenotype; Prognosis

Indexed keywords

DESMIN; GLIAL FIBRILLARY ACIDIC PROTEIN; VIMENTIN; VINCULIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER TISSUE; CONTROLLED STUDY; FEMALE; FIBROGENESIS; FLOW CYTOMETRY; GENE EXPRESSION; GENOME; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MYOFIBROBLAST; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STELLATE CELL;

ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATIC STELLATE CELLS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE ANNOTATION; MYOFIBROBLASTS; PHENOTYPE; PROGNOSIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 84876295797     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-22     Document Type: Article

References (34)

1. Oncogenes and cancer. Croce CM, N Engl J Med 2008 358 502 511 10.1056/NEJMra072367 18234754 (Pubitemid 351185806)
2. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Levine AJ, Puzio-Kuter AM, Science 2010 330 1340 1344 10.1126/science.1193494 21127244
3. Hallmarks of cancer: the next generation. Hanahan D, Weinberg RA, Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230
4. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A, Carcinogenesis 2009 30 1073 1081 10.1093/carcin/bgp127 19468060
5. Risk of HCC: genetic heterogeneity and complex genetics. Dragani TA, J Hepatol 2010 52 252 257 10.1016/j.jhep.2009.11.015 20022654
6. Genetic heterogeneity of hepatocellular carcinoma. Unsal H, Yakicier C, Marcais C, Kew M, Volkmann M, Zentgraf H, Isselbacher KJ, Ozturk M, Proc Natl Acad Sci U S A 1994 91 822 826 10.1073/pnas.91.2.822 8290606 (Pubitemid 24041494)
7. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, N Engl J Med 2008 359 1995 2004 10.1056/NEJMoa0804525 18923165
8. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Cancer Cell 2006 10 99 111 10.1016/j.ccr.2006.06.016 16904609 (Pubitemid 44202603)
9. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nat Med 2006 12 410 416 10.1038/nm1377 16532004
10. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC, J Clin Oncol 2008 26 2707 2716 10.1200/JCO.2007.15.6521 18509183
11. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF, J Hepatol 2011 54 497 505 10.1016/j.jhep.2010.07.044 21112656
12. Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Ju MJ, Qiu SJ, Gao Q, Fan J, Cai MY, Li YW, Tang ZY, Cancer Sci 2009 100 1267 1274 10.1111/j.1349-7006.2009.01182.x 19432885
13. CD133+ hepatic stellate cells are progenitor cells. Kordes C, Sawitza I, Muller-Marbach A, Ale-Agha N, Keitel V, Klonowski-Stumpe H, Haussinger D, Biochem Biophys Res Commun 2007 352 410 417 10.1016/j.bbrc.2006.11.029 17118341 (Pubitemid 44838502)
14. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Friedman SL, Physiol Rev 2008 88 125 172 10.1152/physrev.00013.2007 18195085
15. Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma. Liao R, Sun TW, Yi Y, Wu H, Li YW, Wang JX, Zhou J, Shi YH, Cheng YF, Qiu SJ, Cancer Sci 2012 103 984 992 10.1111/j.1349-7006.2012.02273.x 22417086
16. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Ju MJ, Qiu SJ, Fan J, Xiao YS, Gao Q, Zhou J, Li YW, Tang ZY, Am J Clin Pathol 2009 131 498 510 10.1309/AJCP86PPBNGOHNNL 19289585
17. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Coulouarn C, Corlu A, Glaise D, Guenon I, Thorgeirsson SS, Clement B, Cancer Res 2012 72 2533 2542 10.1158/0008-5472.CAN-11-3317 22419664
18. Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. Sancho-Bru P, Bataller R, Gasull X, Colmenero J, Khurdayan V, Gual A, Nicolas JM, Arroyo V, Gines P, J Hepatol 2005 43 272 282 10.1016/j.jhep.2005.02.035 15964095 (Pubitemid 40956880)
19. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. Jiang F, Parsons CJ, Stefanovic B, J Hepatol 2006 45 401 409 10.1016/j.jhep.2006.03.016 16780995 (Pubitemid 44142112)
20. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF, Gastroenterology 2007 132 1937 1946 10.1053/j.gastro.2007.02. 033 17484886 (Pubitemid 46677935)
21. Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum. Xia Y, Chen R, Song Z, Ye S, Sun R, Xue Q, Zhang Z, J Cancer Res Clin Oncol 2010 136 309 321 10.1007/s00432-009-0666-5 19727817
22. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. Liao R, Sun J, Wu H, Yi Y, Wang JX, He HW, Cai XY, Zhou J, Cheng YF, Fan J, J Exp Clin Cancer Res 2013 32 3 10.1186/1756-9966-32-3 23305119
23. The interleukin-17 pathway is involved in human alcoholic liver disease. Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Hepatology 2009 49 646 657 10.1002/hep.22680 19177575
24. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK, Tang ZY, J Cancer Res Clin Oncol 2004 130 460 468 15146329 (Pubitemid 39119289)
25. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Whittaker S, Marais R, Zhu AX, Oncogene 2010 29 4989 5005 10.1038/onc.2010.236 20639898
26. Vinculin and cellular retinol-binding protein-1 are markers for quiescent and activated hepatic stellate cells in formalin-fixed paraffin embedded human liver. Van Rossen E, Vander Borght S, Van Grunsven LA, Reynaert H, Bruggeman V, Blomhoff R, Roskams T, Geerts A, Histochem Cell Biol 2009 131 313 325 10.1007/s00418-008-0544-2 19052772
27. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T, J Hepatol 2002 36 200 209 11830331 (Pubitemid 34146426)
28. GFAP expression in the liver as an early marker of stellate cells activation. Morini S, Carotti S, Carpino G, Franchitto A, Corradini SG, Merli M, Gaudio E, Ital J Anat Embryol 2005 110 193 207 16536051 (Pubitemid 43311980)
29. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Carotti S, Morini S, Corradini SG, Burza MA, Molinaro A, Carpino G, Merli M, De Santis A, Muda AO, Rossi M, Liver Transpl 2008 14 806 814 10.1002/lt.21436 18508359 (Pubitemid 351895510)
30. Suppression of glial tumor growth by expression of glial fibrillary acidic protein. Toda M, Miura M, Asou H, Sugiyama I, Kawase T, Uyemura K, Neurochem Res 1999 24 339 343 10.1023/A:1022538810581 9972884 (Pubitemid 29067979)
31. Activation of a pro-survival pathway IL-6/JAK2/STAT3 contributes to glial fibrillary acidic protein induction during the cholera toxin-induced differentiation of C6 malignant glioma cells. Shu M, Zhou Y, Zhu W, Wu S, Zheng X, Yan G, Mol Oncol 2011 5 265 272 10.1016/j.molonc.2011.03.003 21470923
32. Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression. Wilhelmsson U, Eliasson C, Bjerkvig R, Pekny M, Oncogene 2003 22 3407 3411 10.1038/sj.onc.1206372 12776191 (Pubitemid 36713737)
33. Hepatitis B virus induced hepatocellular carcinoma. Chemin I, Zoulim F, Cancer Lett 2009 286 52 59 10.1016/j.canlet.2008.12.003 19147276
34. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Fattovich G, Stroffolini T, Zagni I, Donato F, Gastroenterology 2004 127 35 S50 10.1053/j.gastro.2004.09.014 15508101 (Pubitemid 39423368)